
Stay up-to-date with the latest developments in gene and cell therapy by subscribing to our newsletter.
Featured:
Jul 03 | 4D Molecular Therapeutics Accelerates Phase 3 AAV Program for 4D-150 in Wet AMD read more »
Jul 02 | Breakthrough AAV Gene Therapy Restores Hearing in Children and Adults with Genetic Deafness read more »
Jun 30 | Moderna’s mRNA Flu Vaccine Shows Strong Phase 3 Efficacy in Older Adults read more »
News:
Jul 03 | Private Biotech Funding Takes a Steep Dive in H1 2025 read more »
Jul 02 | New Gene Therapy Strategy Rejuvenates CAR T-Cell Effectiveness Against Glioblastoma read more »
Jul 02 | Abeona Therapeutics Strengthens Financial Position with $155 Million Sale of PRV read more »
Jun 30 | AbbVie’s Strategic Leap into In Vivo CAR-T with $2.1 Billion Capstan Acquisition to Transform Autoimmune Disease Treatment read more »
Jun 30 | Arcturus Therapeutics Announces Positive Phase 2 Interim Results for mRNA Therapy in OTC Deficiency read more »
Jun 30 | Neurogene Secures FDA Alignment for Pivotal AAV Gene Therapy Trial (NGN-401) in Rett Syndrome read more »
Jun 27 | FDA Relaxes CAR-T Therapy Requirements, Boosting Access and Commercialization read more »
Jun 27 | Biotech CEOs Urge EU for Urgent Reforms to Boost Cell and Gene Therapy Competitiveness read more »
Articles:
Jul 02 | A genome-wide in vivo CRISPR activation screen identifies BACE1 as a therapeutic vulnerability of lung cancer brain metastasis read more »
Jul 02 | Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery read more »
Jul 02 | Induction of lung mucosal immunity by a next-generation inhaled aerosol COVID-19 vaccine: an open-label, multi-arm phase 1 clinical trial read more »
Jul 02 | A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice read more »
Jul 02 | AAV gene therapy for autosomal recessive deafness 9: a single-arm trial read more »
Jul 01 | Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase read more »
Jul 01 | Single-cell signaling network profiling during redox stress reveals dynamic redox regulation in immune cells read more »
Jul 01 | An mRNA lipid nanoparticle-incorporated nanofiber-hydrogel composite for cancer immunotherapy read more »
Jul 01 | Cellular and biophysical barriers to lipid nanoparticle mediated delivery of RNA to the cytosol read more »
Jul 01 | Peeling back the layers of immunogenicity in CRISPR/Cas9-based genomic medicine read more »
Jul 01 | Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging read more »
Jun 27 | Barriers and solutions for CAR-T therapy in solid tumors read more »
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
